An experimental targeted repair process in which a sequence of DNA of interest is combined with RNA to form a chimeraplast, which binds selectively to the target DNA; once bound, the chimeraplast activates gene repair
ValiGen partners with pharmaceutical and agricultural companies to derive commercial value from its genomics technologies, which provide a continuum of capability from raw profiling of phenotypes to in vivo target validation using its proprietary chimeraplasty DNA repair technology.
In the meantime, a promising new strategy called chimeraplasty, in which the cell is stimulated to repair its own defective genes, has emerged [see "The Promise of Genetic Cures," The World & I, May 2000, p.
Company, said the partnership will combine its new approach to cloning, called chimeraplasty, with the cloning technology developed by the Edinburgh-based Roslin Institute and PPL Therapeutics, Dolly's creators.
While most genetic engineering is hit-or-miss, with scientists having no way of controlling where a gene goes in a cell or knowing whether targeted cells will take up and use the new genes, Kimeragen claims its chimeraplasty technique allows scientists to make precise genetic modifications.
The US company, Kimeragen, said the partnership would combine its new approach to gene therapy, called chimeraplasty, with the cloning technology developed by the Roslin Institute and PPL Therapeutics.
Kimeragen's chimeraplasty technique allows scientists to make precise genetic modifications.
recently merged with the French company ValiGene to form ValiGen.] Whereas gene therapy mainly uses genetically engineered viruses to deliver a replacement gene, chimeraplasty relies on short, synthetically produced sequences of DNA/RNA hybrids (chimeraplasts) to interact with the faulty genetic material and to stimulate the cell's genetic repair mechanism to correct the defects.